LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Search

Bio-Techne Corp

Cerrado

SectorSanidad

43.29 -3.24

Resumen

Variación precio

24h

Actual

Mínimo

43.08

Máximo

45.5

Métricas clave

By Trading Economics

Ingresos

13M

51M

Ventas

16M

311M

P/B

Media del Sector

67.743

51.415

BPA

0.53

Rentabilidad por dividendo

0.66

Margen de beneficios

16.392

Empleados

3,100

EBITDA

22M

100M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+32.43% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.66%

2.34%

Próximas Ganancias

5 ago 2026

Fecha Próximo Dividendo

29 may 2026

Próxima Fecha de Ex Dividendo

18 may 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-1.1B

7.4B

Apertura anterior

46.53

Cierre anterior

43.29

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

155 / 345 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Bio-Techne Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

7 nov 2025, 22:36 UTC

Ganancias

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

Comparación entre iguales

Cambio de precio

Bio-Techne Corp previsión

Precio Objetivo

By TipRanks

32.43% repunte

Estimación a 12 Meses

Media 59.25 USD  32.43%

Máximo 70 USD

Mínimo 49 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Bio-Techne Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

10 ratings

6

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

49.67 / 50.24Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Strong Bearish Evidence

Sentimiento

By Acuity

155 / 345 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.